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E-mail address: martino.bolognesi@unimi.it (M. BoDilated cardiomyopathy (DCM) is a condition whereby the normal muscular function of the myocardium
is altered by speciﬁc or multiple aetiologies. About 25–35% of DCM patients show familial forms of the
disease, with most mutations affecting genes encoding cytoskeletal proteins. Most of the DCM-related
mutations fall in the Lamin AC gene, in particular in the Coil2B domain of the encoded protein. In this con-
text, we focussed our studies on the crystal structures of two lamin Coil2B domain mutants (R335W and
E347K). Both R335 and E347 are higly conserved residues whose substitution has little effects on the
Coil2B domain three-dimensional structure; we can thus hypothesize that the mutations may interfere
with the binding of components within the nuclear lamina, or of nuclear factors, that have been proposed
to interact/associate with lamin A/C.
 2012 Elsevier Inc. All rights reserved.1. Introduction
The eukaryotic cell nucleus is a complex membrane-bound
organelle that houses and organizes the genome, while provid-
ing/supervising its expression. In this context, the lamina, underly-
ing the nuclear membrane, is essential for maintaining nuclear
shape, spacing nuclear pore complexes, anchoring and organizing
heterochromatin [1–4]. Lamina is a meshwork of nuclear-speciﬁc
type V intermediate ﬁlaments (IF) called lamins, associated with
the nuclear membrane, either directly or through interactions with
membrane-bound proteins [2,3,5–8]. As a basic structural unit,
lamins form coiled-coil dimers that associate longitudinally to
form polar head-to-tail polymers [2,9–11]. According to their pri-
mary sequence, biochemical properties and expression patterns,
lamins have been classiﬁed as A- and B-type, which are differen-
tially expressed in cells. The Lamin AC gene (LMNA) maps on the
long arm of chromosome 1 (1q21.2–q21.3) and encodes two main
isoforms by alternative splicing [16], Lamin A and C, which are ex-ll rights reserved.
termediate ﬁlaments; LMNA,
lar dichroism; DLS, dynamic
lognesi).pressed exclusively in differentiated non-proliferating cells
[2,10,12,13].
The translated LMNA protein is a dimer (660 amino acids/
chain) hosting an elongated central a-helical ‘‘rod’’ domain,
ﬂanked by non-a-helical ‘‘head’’ and ‘‘tail’’ domains at the N-
and C-termini, respectively. Each chain contributes to the rod do-
main 350 amino acids that host four a-helical segments, named
1A, 1B, 2A and 2B (in sequential order), with heptad-repeat period-
icity. The four a-helical segments are interconnected by ‘‘linkers’’
termed L1, L12 and L2, which are also held to adopt a-helical con-
formation [14,15]. The 1A, 1B, 2A, 2B a-helical segments build the
coiled coil rod central domain in the LMNA dimer by associating
with the homonymous a-helical segments of the partner chain.
In each LMNA chain, the head domain is about 30 residues and
is predicted to be disordered, while the tail domain contains an
evolutionary conserved 115-residue globular domain exhibiting
an immunoglobulin-like fold [15–17].
Defects in the LMNA gene have been causally linked tomore than
10 different diseases termed laminopathies, with occurrence of car-
diac complications which, in most cases, are dilated cardiomyopa-
thy (DCM) [18–21]. Several laminopathies affect striated muscle
(Emery–Dreifuss muscular dystrophy, dilated cardiomyopathy,
and limb-girdlemuscular dystrophy), whereas others primarily dis-
rupt muscle and neurons (Charcot–Marie–Tooth disorder), adipose
tissue (autosomal dominant partial lipodystrophy), or adipocytes
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athy (DCM) is a myocardial disorder characterized by progressive
ventricular dilation and impaired systolic contraction, being a
major cause of congestive heart failure worldwide [18,25]. Here
we report the crystal structures of two LMNA Coil2B domain mu-
tants (E347K and R335W) that are discussed at the light of their
implications in the context of DCM.2. Materials and methods
2.1. Cloning and mutagenesis
The Coil2B domain (LMNAcc), comprising residues 303–397,
was cloned in pEt151 directional TOPO Expression vector (Invitro-
gen), as a fusion construct comprising an N-terminal hexa-Histidine
afﬁnity tag and a linker (26 residues) containing V5 epitope and TEV
Protease recognition site. Mutagenesis to obtain the R335W and
E347K mutants was performed on LMNAcc using Pfu-Turbo DNA
polymerase (Fermentas), and two synthetic oligonucleotide prim-
ers containing the mutations. Following temperature cycling, the
products were treated with Dpn I, and sequenced by BMR Sequenc-
ing Service, University of Padova, Italy.2.2. Expression and puriﬁcation
LMNAcc w.t. and mutants were expressed in Escherichia coli
strain BL21(DE3) grown in Luria–Bertani medium (Sigma Al-
drich), containing 100 mg/ml ampicillin at 37 C until the OD600
reached 0.8. After cooling the cultures to 25 C, expression of
the recombinant protein was induced by the addition of
0.5 mM isopropyl b-D-thiogalactopyranoside (IPTG) and the
culture was incubated overnight. After induction, the cells were
harvested by centrifugation and resuspended in 100 ml Guanidi-
nium Lysis Buffer (20 mM sodium phosphate pH 7.8, 6 M Guani-
dine HCl, 500 mM NaCl). The cells were lyzed by sonication and
then centrifuged at 23,000g for 1 h at 4 C. The supernatant
was loaded on Nickel Sepharose Fast Flow resin (Ge-Healthcare)
and eluted by gravity in 20 mM NaH2PO4 pH 4, 8 M urea,
500 mM NaCl. The fusion protein was dialyzed overnight into a
refolding buffer (20 mM Tris–HCl pH 8, 150 mM NaCl, 2.4 mM
CaCl2). The buffer was subsequently changed to 10 mM
Tris–HCl pH 8, 500 mM NaCl using a Sephadex PD10 column.
The protein was concentrated to 10 mg/ml using an Amicon Ultra
centrifugal ﬁlter (Millipore).2.3. Circular dichroism (CD)
Circular dichroism (CD) studies were carried out on a Jasco J810
spectropolarimeter. LMNAcc was soluted in 10 mM Tris–HCl pH 8,
500 mMNaCl (8 M urea was added for the control spectrum). Spec-
tra of a 1 mg/ml protein solution were recorded in a 0.1 cm path
length cell and analyzed by means of Jasco J800 software; data
were normalized in terms of Mean Residual Ellipticity ([26]). Esti-
mates of the secondary structure composition were obtained by
means of CDNN version 2.1 (Copyright  Gerald Böhm, Institut
für Biotechnologie, Martin-Luther Universität Halle-Wittenberg).2.4. Dynamic light scattering (DLS)
The freshly puriﬁed proteins were centrifuged at 13,000g for
10 min prior to DLS analysis; all DLS measurements were carried
out at 10 C using a DynaPro instrument (Protein Solution, Char-
lottesville, USA). The DLS data on 10 mg/ml protein solutions
resulted to be sufﬁciently monodisperse (polydispersivity isdeﬁned as the standard deviation of the hydrodynamic radius),
thus suitable for crystallization experiments [27,28].
2.5. Crystallization
Crystallization trials on LMNAcc and mutant solutions, con-
centrated at 10 mg/ml, were performed using an Oryx-8 crystal-
lization robot (Douglas Instruments, East Garston, UK). After two
weeks at 20 C no crystals grew, but vitreous spheres were ob-
served under various growth conditions. To overcome the forma-
tion of undesired vitreous aggregation, the crystallization trials
were incubated at 37 C, at which temperature most of the
spheres turned into crystals.
The largest crystals were obtained under the following condi-
tions: 30% 2-methyl-2,4-pentanediol, 0.1 M Hepes pH 7.5, 0.5 M
Ammonium Sulfate (LMNAcc), 15% Ethanol, 0.1 M Citrate pH 5.5,
0.2 M Lithium Sulfate (R335W), or 30% 2-methyl-2,4-pentanediol,
0.1 M Sodium Acetate pH 4.6, 0.2 M Sodium Chloride (E347K).
Crystals were cryoprotected in their mother liquors, supple-
mented with 25% glycerol and ﬂash-frozen in liquid nitrogen.
X-ray diffraction data were collected at the European Synchro-
tron Radiation Facility (Grenoble, France) on beam line ID23-1.
Crystals of the w.t. LMNAcc and R335W mutant diffracted both
to 3.0 Å, while crystals of the E347K mutant diffracted to 3.6 Å.
All crystals are isomorphous and were shown to belong to the
hexagonal space group P6522. The diffraction data were pro-
cessed using the program iMOSFLM [29] and intensities merged
using Scala [30]; data reduction statistics are reported in Table 1.
The crystal structures were solved by molecular replacement
using the program MOLREP [31]. The LMNAcc structure (PDB
code: 1X8Y [11]) was used as search model. A single protein
molecule was located in the crystal asymmetric unit (statistics
for the molecular replacement solutions are listed in Table 1).
The positioned model molecule was subjected to rigid-body
reﬁnement and reﬁned using REFMAC5 [32]. A random set com-
prising 5% of the data was omitted from reﬁnement for Rfree cal-
culation. The amino acid sequence of the model was modiﬁed to
match the mutants correct sequence and ﬁtted to the electron
density using the program Coot [33]. A set of ﬁnal reﬁnement
cycles was performed using the program Buster [34] until the
Rfactor and Rfree values reached the values listed in Table 1. The
stereochemical quality of the model was checked using the pro-
gram PROCHECK [35]. Atomic coordinates and structure factors
for LMNAcc, R335W and E347K mutants have been deposited
with the PDB [36], with accession codes 3V5B, 3V4Q and
3V4W, respectively.
2.6. Genetic studies
The 12 exons of the LMNA gene were ampliﬁed from peripheral
blood-derived genomic DNA by means of polymerase chain reac-
tion (PCR), using primers derived from intronic sequences [37].
The PCR products were analyzed by means of denaturing high-per-
formance liquid chromatography (Transgenomic, San Jose, CA)
using the Wave DNA Fragment Analysis System. Heteroduplex
fragments were puriﬁed (QIAquick Kit, Qiagen, Santa Clarita, CA)
and then sequenced using a BigDye-terminator cycle sequencing
system (ABI PRISM, Applied Biosystem, Foster City, CA). LMNA gene
analysis was performed by direct bidirectional automated
sequencing in case of probands with healthy parents, to exclude
the rare possibility of recessive forms. The control series for each
mutation is composed of 800 normal individuals. Reference se-
quences used in the study are: LMNA gene: GenBank ID:
NC_000001; LMNAmRNA: GenBank ID: NM_170707; Lamin A pro-
tein: GenBank ID: NP_733821; LMNC mRNA: GenBank ID: NM
005572; Lamin C protein: GenBank ID: NP005563.
Table 1
X-ray data collection and reﬁnement statistics.
LMNAcc R335W E347K
Data collection statistics
Space group P6522 P6522 P6522
Unit-cell parameters (Å, ) a = b = 90.2 c = 74.7
a = b = 90 c = 120
a = b = 90.5 c = 75.4
a = b = 90 c = 120
a = b = 90.2 c = 74.9
a = b = 90 c = 120
Resolution limits (Å) 74.7–3.0 (3.2–3.0) 75.4–3.1 (3.2–3.1) 78.2–3.7 (3.8–3.7)
No of unique reﬂections 3889 (524) 3760 (525) 2316 (314)
Completeness (%) 100 (100) 99.7 (100) 99.1 (95.6)
Redundancy 9.3 (7.9) 9.8 (10.5) 11.6 (9.3)
Rmerge (%)a 5.8 (57) 6.7 (51.7) 11.6 (24.2)
Average I/r (I) 28.6 (3.4) 23.5 (4.5) 19.1 (10.6)
Reﬁnement statistics
Rfactor (%)b 28.0 28.2 33.8
R-free (%)c 33.0 30.5 34.4
Average B (Å2) 101.4 84.0 96.3
R.M.S. bond lengths (Å) 0.009 0.009 0.010
R.M.S. bond angles () 1.13 1.03 1.17
Ramachandran plot
Resid. in most fav. reg. (%) 88.7 98.6 93.0
Resid. in add. allow. reg. (%) 11.3 1.4 7.0
Resid. in disallow. reg. (%) 0.0 0.0 0.0
PDB code 3V5B 3V4Q 3V4W
High resolution shell values in brackets.
a Rmerge =
P
|I – (I)|/
P
I  100, where I is intensity of a reﬂection and (I) is the average intensity.
b Rfactor =
P
|Fo – Fc/
P
Fo  100.
c Rfree is calculated from 5% randomly selected data for crossvalidation.
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3.1. Production and physical characterization of the proteins
We have cloned three recombinant fragments of human LMNA,
which represent the main part of the Coil2B segment (residues
305–397, LMNAcc); these are the wild type LMNAcc, and the two
mutants R335W and E347K. The proteins were produced by refold-
ing from denatured inclusion bodies; thus, the proteins were char-
acterized by biophysical analyses in order to verify their correct
fold after puriﬁcation. We performed a circular dichroism (CD)
analysis on the LMNAcc sample. The CD spectra highlighted a cor-
rectly folded protein composed of 87% a-helical secondary struc-
ture, consistent with the LMNAcc structure, which consists of an
extended a-helix (Fig. 1). The remaining 13% of non a-helical
structure recorded by the CD spectra is likely due to the His-Tag
residues (6 residues) and to the linker between His-Tag and
LMNAcc added in the cloning procedure (26 residues). In order toFig. 1. LMNAcc circular dichroism studies. Main ﬁgure: far-UV CD spectra; inset:
estimation of a-helical content by CDNN software version 2.1.study the stability of the protein, DLS measurements were carried
out at different LMNAcc concentrations. The results showed that at
10 mg/ml LMNAcc proved sufﬁciently monodisperse (19%) to jus-
tify crystallization experiments. The results obtained on LMNAcc
were used as a guideline for preparation of mutant samples.3.2. Overall structure
We could grow crystals of w.t. LMNAcc and the mutant domains
in the hexagonal space group P6522, with one molecule per asym-
metric unit. The protein structure was solved using molecular
replacement techniques and reﬁned to 3.0 and 3.6 Å resolution
(for LMNAcc/R335W, and for E347K, respectively). The ﬁnal crys-
tallographic Rfactor for LMNAcc is 28% and Rfree is 33%; for R335W
Rfactor is 27.4% and Rfree is 28.6%; the E347K structure was reﬁned
to an Rfactor value of 32% and Rfree 34.7% (see Table 1). Both w.t.
and mutant models comprise amino acids 313–386 (sequence
numbers refer to full length LMNA). Superimposition of LMNAcc
and its mutants showed that the overall conformation of the mol-
ecules is strongly conserved, as expected considering the single
residue mutations and crystal isomorphism. Nevertheless, all the
three protein structures appear progressively disordered towards
the N-terminus. In particular, the ﬁrst eight N-terminal residues
(305–312) and the thirty-six tail residues added in the cloning pro-
cedure could not be modelled (while revealing some residual weak
electron density). Residues 313–315 exhibit only poor density,
which was however sufﬁcient to trace the helix path unambigu-
ously; the rest of the structure exhibits fairly good electron density.
The ﬁnal models display excellent overall stereochemical parame-
ters as reported in Table 1. The overall structure of the crystallized
LMNAcc consists essentially of a single long a-helix (Fig. 2A). How-
ever, around residues 345–355 LMNAcc displays a discontinuity of
the heptad-repeat, the so-called ‘‘stutter’’, that is an insertion of
four extra residues occurring roughly at the center of segment 2B
in all IF proteins [38]. The crystallographic analyses revealed that
w.t. and mutant LMNAcc display one polypeptide chain per asym-
metric unit. However, LMNAcc builds up a parallel coiled coil
dimer, as reported for the full length protein, through assembly
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(Fig. 2B). The dimer is positioned on a crystallographic 2-fold axis,
and exhibits a number of intermolecular salt bridges, which stabi-
lize association of the two chains in two main regions at the ter-
mini of the domain (residues 313–321 and 369–376). In addition
to the canonical coiled coil hydrophobic packing, two main salt
bridges are found that probably contribute to the speciﬁcity of this
interaction. The ﬁrst occurs between residue Glu342 and the side
chain of Lys341 from the opposed chain in the coil. The second salt
bridge links Arg331 and Glu330, again of the opposed LMNAcc
chain.3.3. Structure of DCM-related mutations in Coil2B domain
Most of the more than 100 mutations related to human DCM
fall in the lamin A rod domain [18,25,37]. The side chains ofFig. 2. LMNAcc models from the crystallographic analyses. (A) Cartoon representation
asymmetric unit. The stutter region, breaking the a-helical continuity, is deﬁned by a th
Fig. 3. Crystal structures of the mutated LMNAcc. (A) View of the mutated region of R33
(1r above the mean) around the central (mutated) region of the R335Wmutant is shown
is referred to the web version of this article.)Arg335 and Glu347, mutated in this work, are shown by the crystal
structures to be exposed at the surface of the coiled coil dimer
(Fig. 3); nevertheless, the mutations occur at sites that are highly
conserved in the known LMNA amino acid sequences [11,39].
Within the vertebrate IF superfamily, Arg335 is a highly conserved
residue, stressing its key role in the correctly folded coil/rod. A
mutation to Trp may hamper stability of the coiled-coil, either be-
cause of steric hindrance or charge modiﬁcation. A destabilization
of the quaternary assembly, or the achievement of a looser coil,
may be at the roots of the pathogenic effect of the R335W muta-
tion, although the substitution of Arg335 with Trp does not perturb
the overall conformation of the helix. The second mutated residue,
Glu347, is highly conserved through the phyla, except for the
invertebrate lamins. The substitution with a positively charged res-
idue, as Lys, might interfere with the formation of an intra- or
inter-helical salt bridge, or other forms of polar interaction. Bothof LMNAcc as a monomer, and (B) as the dimer hosted in the crystallographic
in line and labelled.
5W, and (B) E347K. Substituted residues are in red. The 2Fo–Fc electron-density map
in (C). (For interpretation of the references to colour in this ﬁgure legend, the reader
M. Bollati et al. / Biochemical and Biophysical Research Communications 418 (2012) 217–221 221mutations may alter the interactions of the coiled-coil dimer, and
consequently interfere with the lamina assembly; alternatively,
they may affect the binding of components within the nuclear lam-
ina, including nuclear factors, that have been proposed to interact/
associate with LMNA [40–43].
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